SEATTLE--(BUSINESS WIRE)--According to Coherent Market Insights, the global CRISPR and CAS gene Market was valued at US$ 1,388.1 million in 2017, and is projected to exhibit a CAGR of 20.8% during the forecast period (2018 – 2026).
Key Trends and Analysis of the CRISPR and CAS Gene market:
The CRISPR and CAS Gene market size is expected to witness significant growth rate, owing to increasing research & development along with increasing demand for clinical trials for the development of new technologies in CRISPR and CAS gene therapy to treat cancer. For instance, The Parker Institute for Cancer Immunotherapy, agreed to sponsor the first in-human clinical trials of CRISPR-enabled technology targeting three types of cancer. The trial, led by the University of Pennsylvania, used CRISPR-modified T-cells, a part of the human immune system, to treat myeloma, melanoma, and sarcoma. The trial was commenced in 2017.
Request Sample Copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/2598
Moreover, key players are more focused on working in collaborations for producing novel CRISPR and CAS technology for different therapeutic areas. For instance, in October 2018 CRISPR Therapeutics and Vertex Pharmaceuticals' collaborated for gene-editing clinical trial, to develop and commercialize new breakthrough therapeutics to cure blood disorders, and congenital heart disease using the CRISPR/Cas9 technology to start in the U.S. The trial was scheduled to start by the end of 2018, according to a joint statement from the companies.
To know the latest trends and insights prevalent in this market, click the link below:
https://www.coherentmarketinsights.com/market-insight/crispr-and-cas-gene-market-2598
Key Market Takeaways:
- The global CRISPR and CAS gene Market is projected to witness CAGR of 20.8% during the forecast period (2018 – 2026), owing to increasing research and development in for different therapeutic area. Research institutes are developing gene therapy to cure AIDS. For instance, in May 2018, researchers at Kobe University in Japan successfully destroyed and deleted the regulatory genes of HIV-1 using the genome editing system CRISPR/Cas9, thereby successfully blocking the production of HIV-1 by infected cells.
- Among region, North America is expected to show significant growth in CRISPR and CAS gene market revenue, owing to increasing research and development on CRISPR and CAS gene therapy. In 2017, Editas partnered with Juno Therapeutics for cancer-related research using CRISPR under the terms of the agreement. Editas has also engaged in a three-year research and development (R&D) collaboration deal with San Raffaele Telethon Institute for Gene Therapy to research and develop next generation stem cell and T-cell therapies for the treatment of rare diseases.
- Major players operating in the CRISPR and CAS gene market include Caribou Biosciences Inc., CRISPR Therapeutics, Mirus Bio LLC, Editas Medicine, Takara Bio Inc., Synthego, Thermo Fisher Scientific, Inc., GenScript, Addgene, Merck KGaA (Sigma-Aldrich), Integrated DNA Technologies, Inc., Transposagen Biopharmaceuticals, Inc., OriGene Technologies, Inc., New England Biolabs, Dharmacon, Cellecta, Inc., Agilent Technologies, and Applied StemCell, Inc.
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
